BMYBristol-Myers SquibbFinished
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Advanced Solid Tumor
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 44 (final count)
- Started
- Jul 14, 2020
- Main results expected
- Aug 22, 2024
- Fully finished
- Aug 22, 2024
- Results posted
- Dec 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events and Deaths
Measured over: From first dose (Day 1) and 100 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: From first dose (Day 1) untill Day 28
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04349267 · record last updated 2025-12-17 · checked 2026-11-09 15:47 UTC